Sanofi

Out to revive R&D, a resurgent Sanofi pays $150M cash to partner up with a pioneering protein degradation player
Out to revive R&D, a resurgent Sanofi pays $150M cash to partner up with a pioneering protein degradation player
Endpoints
Sanofi
protein degradation
immunology
R&D
Kymera
Flag link:
Sanofi Licenses Natural Killer Cancer Program from Kiadis in $987 Million Deal
Sanofi Licenses Natural Killer Cancer Program from Kiadis in $987 Million Deal
BioSpace
Kiadis
Sanofi
natural killer cell therapies
Flag link:
AstraZeneca, Lilly, Sanofi and others raise prices to start July: report
AstraZeneca, Lilly, Sanofi and others raise prices to start July: report
Fierce Pharma
AstraZeneca
Eli Lilly
Sanofi
drug pricing
GSK
Biogen
Flag link:
Sanofi, Regeneron shut down Kevzara trial in COVID-19 after finding no benefit for ventilated patients
Sanofi, Regeneron shut down Kevzara trial in COVID-19 after finding no benefit for ventilated patients
Fierce Pharma
Sanofi
Regeneron
Kevzara
clinical trials
COVID-19
Flag link:
GSK and Sanofi close in on £500m COVID-19 vaccine deal with UK – report
GSK and Sanofi close in on £500m COVID-19 vaccine deal with UK – report
Pharmaforum
GSK
Sanofi
UK
vaccines
COVID-19
pandemic
Flag link:
Biopharma Companies Continue to Expand, Add Jobs Despite Ongoing Pandemic
Biopharma Companies Continue to Expand, Add Jobs Despite Ongoing Pandemic
BioSpace
pharma industry
biotech
pandemic
COVID-19
hirings
AGC Biologics
Grail
Grifols
CRISPR Therapeutics
Sana Biotechnology
Point
Sanofi
Medpharm
Regeneron
Flag link:
Sanofi Streamlines Pipeline Focus While Looking Ahead to a Post-COVID-19 World
Sanofi Streamlines Pipeline Focus While Looking Ahead to a Post-COVID-19 World
BioSpace
Sanofi
R&D
COVID-19
pandemic
Flag link:
Sanofi Considering Additional Restructuring and Up to 1,000 Job Cuts
Sanofi Considering Additional Restructuring and Up to 1,000 Job Cuts
BioSpace
Sanofi
restructuring
layoffs
Flag link:
Merck treads on Sanofi, Regeneron's turf with Keytruda's latest skin cancer OK
Merck treads on Sanofi, Regeneron's turf with Keytruda's latest skin cancer OK
Fierce Pharma
Merck
Keytruda
FDA
squamous cell carcinoma
Sanofi
Regeneron
Libtayo
Flag link:
Sanofi's fight for a better research reputation
Sanofi's fight for a better research reputation
BioPharma Dive
Sanofi
R&D
cancer
immune disorders
Flag link:
Sanofi’s third Translate collaboration sees big bucks at last
Sanofi’s third Translate collaboration sees big bucks at last
EP Vantage
Sanofi
vaccines
Translate Bio
MRNA
Flag link:
Third-quarter events to watch for large drug makers
Third-quarter events to watch for large drug makers
EP Vantage
Biogen
aducanumab
Sanofi
THOR-707
Bristol-Myers Squibb
pegbelfermin
Eli Lilly
FDA
Flag link:
Sanofi, Regeneron Win China Approval For Dupixent Dermatitis Drug
Sanofi, Regeneron Win China Approval For Dupixent Dermatitis Drug
Yahoo/SmarterAnalyst
Sanofi
Regeneron
China
Dupixent
atopic dermatitis
Flag link:
Amicus shares surge as Sanofi struggles to raise a cheer for mixed pivotal data for a PhIII contender — and analysts blow a raspberry
Amicus shares surge as Sanofi struggles to raise a cheer for mixed pivotal data for a PhIII contender — and analysts blow a raspberry
Endpoints
Sanofi
Amicus Therapeutics
clinical trials
Pompe disease
Avalglucosidase alfa
Lumizyme
Flag link:
Sanofi pumps $554M into new vaccine manufacturing facility in eastern France
Sanofi pumps $554M into new vaccine manufacturing facility in eastern France
Fierce Pharma
Sanofi
vaccines
drug manufacturing
France
Flag link:
ADA: Sanofi bolsters Soliqua with real-world data showing starting insulin, GLP-1 together helps control blood sugar
ADA: Sanofi bolsters Soliqua with real-world data showing starting insulin, GLP-1 together helps control blood sugar
Fierce Pharma
ADA
diabetes
Sanofi
Soliqua
type 2 diabetes
Flag link:
ADA: Novo Nordisk's long-lasting insulin candidate matches Lantus in phase 2
ADA: Novo Nordisk's long-lasting insulin candidate matches Lantus in phase 2
Fierce Pharma
ADA
diabetes
Novo Nordisk
insulin icodec
Sanofi
Lantus
insulin
Flag link:
Mylan and Biocon Gain FDA Approval for Insulin Equivalent to Sanofi's Lantus
Mylan and Biocon Gain FDA Approval for Insulin Equivalent to Sanofi's Lantus
Motley Fool
FDA
Mylan
Biocon
Semglee
Sanofi
insulin
Lantus
diabetes
Flag link:
AAD 2020 – Leo’s eczema wildcard proves tame
AAD 2020 – Leo’s eczema wildcard proves tame
EP Vantage
LEO Pharma
Sanofi
Regeneron
eczema
atopic dermatitis
AAD
tralokinumab
Flag link:
After Disappointing Study Results, Denali and Sanofi Shift Resources to a Different Alzheimer's Drug
After Disappointing Study Results, Denali and Sanofi Shift Resources to a Different Alzheimer's Drug
BioSpace
Denali Therapeutics
Sanofi
DNL747
ALS
Alzheimer's disease
DNL788
clinical trials
Flag link:

Pages